News > ALS patients contend with $158K price tag on new drug

ALS patients contend with $158K price tag on new drug

For two years, Becky Mourey pushed the FDA to approve an experimental drug for Lou Gehrig’s disease. In September, Relyvrio became only the third drug approved in the U.S. for ALS an incurable neurodegenerative disease that is usually fatal within five years. But patients and physicians who celebrated Relyvrio’s approval several months ago are now contending with the obstacles posed by the U.S. healthcare system.